Stockscreener 앱 받기
4.89
1.24%
0.06
시장 영업 전:
4.94
0.05
+1.02%
전일 마감가:
$4.83
열려 있는:
$4.87
하루 거래량:
11.38M
Relative Volume:
0.43
시가총액:
$2.09B
수익:
$64.60M
순이익/손실:
$-377.75M
주가수익비율:
-3.1548
EPS:
-1.55
순현금흐름:
$-335.64M
1주 성능:
+2.52%
1개월 성능:
-24.65%
6개월 성능:
-36.25%
1년 성능:
-35.74%
1일 변동 폭
$4.825
$4.9399
1주일 범위
$4.72
$5.17
52주 변동 폭
$3.79
$12.36
리커젼 파마 Stock (RXRX) Company Profile
명칭
Recursion Pharmaceuticals Inc
전화
(385) 269-0203
주소
41S RIO GRANDE STREET, SALT LAKE CITY
RXRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RXRX
Recursion Pharmaceuticals Inc
|
4.89 | 2.10B | 64.60M | -377.75M | -335.64M | -1.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
389.08 | 99.27B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
586.96 | 62.28B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.18 | 59.14B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
707.96 | 43.34B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
300.14 | 36.72B | 3.81B | -644.79M | -669.77M | -6.24 |
리커젼 파마 Stock (RXRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-03 | 재개 | Morgan Stanley | Equal-Weight |
| 2023-05-22 | 개시 | Morgan Stanley | Equal-Weight |
| 2023-03-16 | 개시 | Needham | Buy |
| 2022-09-16 | 개시 | KeyBanc Capital Markets | Overweight |
| 2022-04-18 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-03-04 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2021-09-21 | 개시 | Berenberg | Buy |
| 2021-05-11 | 개시 | BofA Securities | Buy |
| 2021-05-11 | 개시 | Goldman | Neutral |
| 2021-05-11 | 개시 | JP Morgan | Neutral |
| 2021-05-11 | 개시 | KeyBanc Capital Markets | Overweight |
| 2021-05-11 | 개시 | SVB Leerink | Outperform |
모두보기
리커젼 파마 주식(RXRX)의 최신 뉴스
Volatility clustering patterns for Recursion Pharmaceuticals Inc.Market Sentiment Report & Growth Focused Stock Reports - Newser
Tools to monitor Recursion Pharmaceuticals Inc. recovery probabilityWeekly Stock Analysis & Daily Growth Stock Investment Tips - Newser
Using AI based signals to follow Recursion Pharmaceuticals Inc.Rate Cut & Weekly High Potential Stock Alerts - Newser
Recursion Pharmaceuticals Inc. stock prediction for this weekTrade Analysis Report & Verified Entry Point Signals - Newser
Combining price and volume data for Recursion Pharmaceuticals Inc.July 2025 Summary & Trade Opportunity Analysis Reports - Newser
Will Recursion Pharmaceuticals Inc. stock recover after recent dropRate Hike & Free Community Supported Trade Ideas - Newser
Visualizing Recursion Pharmaceuticals Inc. stock with heatmaps2025 Price Targets & Low Drawdown Investment Strategies - Newser
Pattern recognition hints at Recursion Pharmaceuticals Inc. upside2025 Trading Recap & Daily Growth Stock Tips - Newser
Market reaction to Recursion Pharmaceuticals Inc.’s recent newsPortfolio Risk Summary & Daily Stock Trend Watchlist - Newser
Building trade automation scripts for Recursion Pharmaceuticals Inc.Trade Volume Report & Low Risk High Win Rate Stock Picks - Newser
Tools to assess Recursion Pharmaceuticals Inc.’s risk profileStock Surge & Breakout Confirmation Trade Signals - Newser
Multi factor analysis applied to Recursion Pharmaceuticals Inc.Weekly Trade Analysis & High Accuracy Swing Entry Alerts - Newser
Does Recursion Pharmaceuticals Inc. qualify in momentum factor screeningInflation Watch & Free Expert Verified Stock Movement Alerts - Newser
Real time breakdown of Recursion Pharmaceuticals Inc. stock performanceWeekly Trade Recap & Weekly Return Optimization Alerts - Newser
Quantitative breakdown of Recursion Pharmaceuticals Inc. recent moveWeekly Gains Report & Fast Exit Strategy with Risk Control - Newser
Is it too late to sell Recursion Pharmaceuticals Inc.Sell Signal & AI Enhanced Trading Signals - Newser
Ranking Recursion Pharmaceuticals Inc. among high performing stocks via toolsDay Trade & AI Enhanced Execution Alerts - Newser
Earnings visualization tools for Recursion Pharmaceuticals Inc.Weekly Profit Analysis & Low Risk Profit Maximizing Plans - Newser
Will Recursion Pharmaceuticals Inc. continue its uptrendJuly 2025 Sector Moves & Daily Volume Surge Signals - Newser
Is Recursion Pharmaceuticals Inc. building a consolidation base2025 Key Lessons & Free Reliable Trade Execution Plans - Newser
Understanding Recursion Pharmaceuticals Inc.’s price movement2025 Market Outlook & AI Forecast Swing Trade Picks - Newser
Applying chart zones and confluence areas to Recursion Pharmaceuticals Inc.Market Growth Summary & Stock Portfolio Risk Control - Newser
Recursion's Strategic Conference Participation and AI-Driven Drug Discovery Model - AInvest
Recursion to Participate in Upcoming Investor Conferences - MarketScreener
Historical volatility pattern of Recursion Pharmaceuticals Inc. visualized2025 Market Trends & Growth Focused Stock Pick Reports - Newser
Sector ETF performance correlation with Recursion Pharmaceuticals Inc.Weekly Trade Summary & Accurate Entry and Exit Point Alerts - Newser
Backtesting results for Recursion Pharmaceuticals Inc. trading strategiesJuly 2025 Sentiment & Fast Momentum Entry Tips - Newser
Visual analytics tools that track Recursion Pharmaceuticals Inc. performanceEarnings Risk Report & Weekly Top Stock Performers List - Newser
Full technical analysis of Recursion Pharmaceuticals Inc. stockMarket Growth Report & Technical Entry and Exit Alerts - Newser
Nvidia CEO Jensen Huang Was Dubbed 'Godfather of AI.' The Company Is Betting On These AI Stocks - Investopedia
Recursion Pharmaceuticals Inc. Chart Enters High Volatility Zone getLinesFromResByArray error: size == 0 - kangso.co.kr
Will Recursion Pharmaceuticals Inc. benefit from macro trendsJuly 2025 Institutional & Real-Time Chart Pattern Alerts - Newser
Measuring Recursion Pharmaceuticals Inc.’s beta against major indicesJuly 2025 PreEarnings & Risk Controlled Daily Trade Plans - Newser
What’s the recovery path for long term holders of Recursion Pharmaceuticals Inc.Quarterly Investment Review & Low Risk Investment Opportunities - Newser
Can Recursion Pharmaceuticals Inc. hit a new high this monthJuly 2025 Price Swings & Reliable Price Breakout Signals - Newser
1 Reason to Buy This Beaten-Down Artificial Intelligence (AI) Stock, and 2 Reasons to Sell - Yahoo Finance
Needham Maintains Buy Rating on Recursion (RXRX) - MSN
Recursion Pharmaceuticals Inc. stock outlook for YEARWeekly Market Summary & Target Return Focused Stock Picks - Newser
Live market analysis of Recursion Pharmaceuticals Inc.2025 Market Trends & Scalable Portfolio Growth Methods - Newser
Recursion Pharmaceuticals (RXRX) Drops on 3rd Day as Company Execs Dispose of Shares - MSN
Recursion Pharmaceuticals (RXRX): A High-Risk, High-Reward Play in the AI-Driven Drug Discovery Revolution - AInvest
리커젼 파마 (RXRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.98%
8.06%
자본화:
|
볼륨(24시간):